Last reviewed · How we verify
Gliflozin
At a glance
| Generic name | Gliflozin |
|---|---|
| Sponsor | Fayoum University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction (PHASE3)
- Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program
- Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. (NA)
- Surgical or Medical Treatment (PHASE4)
- Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease (PHASE3)
- Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
- The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure (PHASE4)
- SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |